Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Akebia Therapeutics, Inc. has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, indicating that each pending matter is being reviewed by a different individual.
The prosecution activity spans 3 distinct art units, suggesting technical variety within the Biotechnology & Pharmaceuticals filings. NOTTINGHAM, KYLE GREGORY is the busiest examiner, though they are responsible for only 1 busiest examiner pending action. This indicates that the 4 pending office actions are distributed across the 4 distinct examiners.
The use of 3 distinct art units for the current workload shows that the company's Biotechnology & Pharmaceuticals portfolio is being examined across multiple specialized groups at the patent office. With 4 distinct examiners involved, the company must manage multiple simultaneous dialogues during prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18742035 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOTTINGHAM, KYLE GREGORY | — |
| 18542100 | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | SZPERKA, MICHAEL EDWARD | — |
| 18041490 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1621 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18742035 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOTTINGHAM, KYLE GREGORY | — | §102§103§112DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18542100 | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | SZPERKA, MICHAEL EDWARD | 1641 | DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18500471 | Compositions and Methods for Treating Anemia | YOO, SUN JAE | 1621 | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18041490 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SHIM, DAVID M. | 1626 | §103 | Final Rejection | — | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial